A $44 billion biotech just got some good news from the FDA about a key Alzheimer's drug, and the stock is soaring
Biogenand Eisai said their experimental Alzheimer'sdrug will be reviewed more quickly by regulators at the US Food and Drug Administration.
- If the drug is approved, it would be the first treatment to reduce the clinical decline of Alzheimer's disease.
- The companies abandoned the drug in 2019, saying it didn't work, only to revive it months later.
- In response to this news, shares of Biogen were up about 9%.
The biotech giant Biogen just said US regulators will give its potential Alzheimer's treatment a speedy review, sending the company's stock soaring.
The US Food and Drug Administration will rule on the company's treatment, called aducanumab, by March 7, Biogen and its research partner Eisai said in a statement. After the announcement, Biogen's shares climbed about 9%, giving the company a market value of $44 billion.
Biogen CEO Michel Vounatsos called the news "an important step in the path to potentially having a treatment that meaningfully changes the course of Alzheimer's disease," in a statement.
If this application goes well, this would be the first Alzheimer's drug to reduce the cognitive decline of the illness. The drug works by targeting the protein amyloid beta in the brain.
The company abandoned further development of the drug after disappointing trials in 2019, then resumed work on it later that year.
- We asked ChatGPT who the greatest athlete of all time is and it did not go well for LeBron James
- A man kept the same pair of contact lenses in for 3 years, causing permanent astigmatism and buildup behind his eyelids. His doctor said he's not responsible enough to wear contacts.
- Clarence Thomas wrote a scathing, nearly 50-page dissent about why the Supreme Court should have gutted voting rights
- Railway jobs: 12,000 recruited under 'Rozgar Mela' initiative
- List of famous things to buy in Goa
- Realme 11 Pro 5G review – a mid-ranger with a premium design
- Realme 11 Pro+ 5G Review: Affordable luxury with some rough edges
- Learning curve: Edtechs at a crossroad